Book contents
- Genome Editing and Engineering
- Genome Editing and Engineering
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Preface
- Part I Biology of Endonucleases (Zinc-Finger Nuclease, TALENs and CRISPRs) and Regulatory Networks
- Part II Genome Editing in Model Organisms
- Part III Technology Development and Screening
- Part IV Genome Editing in Stem Cells and Regenerative Biology
- Part V Genome Editing in Disease Biology
- 21 CRISPR/Cas9-based In Vivo Models of Cancer
- 22 Inducible CRISPR-based Genome Editing for the Characterization of Cancer Genes
- 23 Genome Editing for Retinal Diseases
- 24 Manipulation of Long Non-coding RNAs in Cardiovascular Disease Using Genome Editing Technology
- 25 Gene Silencing, Disruption and Latency Reactivation with RNA-based and Gene Editing CRISPR/Cas, ZFN and TALEN Technologies for HIV-1/AIDS Therapies
- 26 Use of the CRISPR/Cas9 System for Genome Editing of Immune System Cells, Defense Against HIV-1 and Cancer Therapies
- 27 Harnessing the Therapeutic Potential of Long Non-coding RNAs in Immunity
- Part VI Legal (Intellectual Property) and Bioethical Issues of Genome Editing
- Index
- Plate Section (PDF Only)
- References
22 - Inducible CRISPR-based Genome Editing for the Characterization of Cancer Genes
from Part V - Genome Editing in Disease Biology
Published online by Cambridge University Press: 30 July 2018
Book contents
- Genome Editing and Engineering
- Genome Editing and Engineering
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Preface
- Part I Biology of Endonucleases (Zinc-Finger Nuclease, TALENs and CRISPRs) and Regulatory Networks
- Part II Genome Editing in Model Organisms
- Part III Technology Development and Screening
- Part IV Genome Editing in Stem Cells and Regenerative Biology
- Part V Genome Editing in Disease Biology
- 21 CRISPR/Cas9-based In Vivo Models of Cancer
- 22 Inducible CRISPR-based Genome Editing for the Characterization of Cancer Genes
- 23 Genome Editing for Retinal Diseases
- 24 Manipulation of Long Non-coding RNAs in Cardiovascular Disease Using Genome Editing Technology
- 25 Gene Silencing, Disruption and Latency Reactivation with RNA-based and Gene Editing CRISPR/Cas, ZFN and TALEN Technologies for HIV-1/AIDS Therapies
- 26 Use of the CRISPR/Cas9 System for Genome Editing of Immune System Cells, Defense Against HIV-1 and Cancer Therapies
- 27 Harnessing the Therapeutic Potential of Long Non-coding RNAs in Immunity
- Part VI Legal (Intellectual Property) and Bioethical Issues of Genome Editing
- Index
- Plate Section (PDF Only)
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Genome Editing and EngineeringFrom TALENs, ZFNs and CRISPRs to Molecular Surgery, pp. 337 - 357Publisher: Cambridge University PressPrint publication year: 2018
References
Banaszynski, LA, Chen, LC, Maynard-Smith, LA, Ooi, AG, Wandless, TJ. 2006. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126(5): 995–1004.CrossRefGoogle ScholarPubMed
Banaszynski, LA, Sellmyer, MA, Contag, CH, Wandless, TJ, Thorne, SH. 2008. Chemical control of protein stability and function in living mice. Nat Med 14(10): 1123–1127.CrossRefGoogle ScholarPubMed
Bell, JB, Podetz-Pedersen, KM, Aronovich, EL, et al. 2007. Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection. Nat Protoc 2(12): 3153–3165.CrossRefGoogle ScholarPubMed
Boj, SF, Hwang, CI, Baker, LA, et al. 2015. Organoid models of human and mouse ductal pancreatic cancer. Cell 160(1–2): 324–338.CrossRefGoogle ScholarPubMed
Bonger, KM, Chen, LC, Liu, CW, Wandless, TJ. 2011. Small-molecule displacement of a cryptic degron causes conditional protein degradation. Nat Chem Biol 7(8): 531–537.CrossRefGoogle ScholarPubMed
Chavez, A, Scheiman, J, Vora, S, et al. 2015. Highly efficient Cas9-mediated transcriptional programming. Nat Methods 12(4): 326–328.CrossRefGoogle ScholarPubMed
Clackson, T, Yang, W, Rozamus, LW, et al. 1998. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci USA 95(18): 10437–10442.CrossRefGoogle ScholarPubMed
Davis, KM, Pattanayak, V, Thompson, DB, Zuris, JA, Liu, DR. 2015. Small molecule-triggered Cas9 protein with improved genome-editing specificity. Nat Chem Biol 11(5): 316–318.CrossRefGoogle ScholarPubMed
Doudna, JA, Charpentier, E. 2014. Genome editing: the new frontier of genome engineering with CRISPR-Cas9. Science 346(6213): 1258096.CrossRefGoogle ScholarPubMed
Doudna, JA, Sontheimer, EJ. 2014. Methods in enzymology. The use of CRISPR/Cas9, ZFNs, and TALENs in generating site-specific genome alterations. Preface. Methods Enzymol 546: xix–xx.CrossRefGoogle ScholarPubMed
Dow, LE, Fisher, J, O’Rourke, KP, et al. 2015. Inducible in vivo genome editing with CRISPR-Cas9. Nat Biotechnol 33(4): 390–394.CrossRefGoogle ScholarPubMed
Dow, LE, Lowe, SW. 2012.Life in the fast lane: mammalian disease models in the genomics era. Cell 148(6): 1099–1109.CrossRefGoogle ScholarPubMed
DuPage, M, Dooley, AL, Jacks, T. 2009. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4(7): 1064–1072.CrossRefGoogle ScholarPubMed
Dutta, A, Stillman, B. 1992. cdc2 family kinases phosphorylate a human cell DNA replication factor, RPA, and activate DNA replication. EMBO J 11(6): 2189–2199.CrossRefGoogle ScholarPubMed
Hanahan, D, Weinberg, RA. 2011. Hallmarks of cancer: the next generation. Cell 144(5): 646–674.CrossRefGoogle ScholarPubMed
Iwamoto, M, Bjorklund, T, Lundberg, C, Kirik, D, Wandless, TJ. 2010. A general chemical method to regulate protein stability in the mammalian central nervous system. Chem Biol 17(9): 981–988.CrossRefGoogle ScholarPubMed
Jinek, M, Chylinski, K, Fonfara, I, et al. 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096): 816–821.CrossRefGoogle ScholarPubMed
Konermann, S, Brigham, MD, Trevino, AE, et al. 2015. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517(7536): 583–588.CrossRefGoogle ScholarPubMed
Maddalo, D, Manchado, E, Concepcion, CP, et al. 2014. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516(7531): 423–427.CrossRefGoogle ScholarPubMed
McJunkin, K, Mazurek, A, Premsrirut, PK, et al. 2011. Reversible suppression of an essential gene in adult mice using transgenic RNA interference. Proc Natl Acad Sci USA 108(17): 7113–7118.CrossRefGoogle ScholarPubMed
Nihongaki, Y, Kawano, F, Nakajima, T, Sato, M. 2015. Photoactivatable CRISPR-Cas9 for optogenetic genome editing. Nat Biotechnol 33(7): 755–760.CrossRefGoogle ScholarPubMed
Platt, RJ, Chen, S, Zhou, Y, et al. 2014. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159(2): 440–455.CrossRefGoogle ScholarPubMed
Premsrirut, PK, Dow, LE, Kim, SY, et al. 2011. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 145(1): 145–158.CrossRefGoogle ScholarPubMed
Senturk, S, Shirole, NH, Nowak, DG, et al. 2017. Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization. Nat Commun 8: 14370.CrossRefGoogle ScholarPubMed
Shi, J, Wang, E, Milazzo, JP, et al. 2015. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol 33(6): 661–667.CrossRefGoogle ScholarPubMed
Singh, P, Schimenti, JC, Bolcun-Filas, E. 2015. A mouse geneticist’s practical guide to CRISPR applications. Genetics 199(1): 1–15.CrossRefGoogle ScholarPubMed
Sternberg, SH, Redding, S, Jinek, M, Greene, EC, Doudna, JA. 2014. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 507(7490): 62–67.CrossRefGoogle ScholarPubMed
Swiech, L, Heidenreich, M, Banerjee, A, et al. 2015. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 33(1): 102–106.CrossRefGoogle ScholarPubMed
Tyner, SD, Venkatachalam, S, Choi, J, et al. 2002. p53 mutant mice that display early ageing-associated phenotypes. Nature 415(6867): 45–53.CrossRefGoogle ScholarPubMed
Utomo, AR, Nikitin, AY, Lee, WH. 1999. Temporal, spatial, and cell type-specific control of Cre-mediated DNA recombination in transgenic mice. Nat Biotechnol 17(11): 1091–1096.CrossRefGoogle ScholarPubMed
Ventura, A, Kirsch, DG, McLaughlin, ME, et al. 2007. Restoration of p53 function leads to tumour regression in vivo. Nature 445(7128): 661–665.CrossRefGoogle ScholarPubMed
Wang, T, Birsoy, K, Hughes, NW, et al. 2015. Identification and characterization of essential genes in the human genome. Science 350(6264): 1096–1101.CrossRefGoogle ScholarPubMed
Wright, AV, Nunez, JK, Doudna, JA. 2016. Biology and applications of CRISPR systems: harnessing nature’s toolbox for genome engineering. Cell 164(1–2): 29–44.CrossRefGoogle Scholar
Wright, AV, Sternberg, SH, Taylor, DW, et al. 2015. Rational design of a split-Cas9 enzyme complex. Proc Natl Acad Sci USA 112(10): 2984–2989.CrossRefGoogle ScholarPubMed
Xue, W, Chen, S, Yin, H, et al. 2014. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514(7522): 380–384.CrossRefGoogle ScholarPubMed
Yang, H, Wang, H, Jaenisch, R. 2014. Generating genetically modified mice using CRISPR/Cas-mediated genome engineering. Nat Protoc 9(8): 1956–1968.CrossRefGoogle ScholarPubMed
Yang, H, Wang, H, Shivalila, CS, et al. 2013. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154(6): 1370–1379.CrossRefGoogle ScholarPubMed
Yao, Z, Fenoglio, S, Gao, DC, et al. 2010. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 107(35): 15535–15540.CrossRefGoogle ScholarPubMed
Zou, L, Elledge, SJ. 2003. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300(5625): 1542–1548.CrossRefGoogle ScholarPubMed
Zou, Y, Liu, Y, Wu, X, Shell, SM. 2006. Functions of human replication protein A (RPA): from DNA replication to DNA damage and stress responses. J Cell Physiol 208(2): 267–273.CrossRefGoogle ScholarPubMed
Zuber, J, Shi, J, Wang, E, et al. 2011. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478(7370): 524–528.CrossRefGoogle ScholarPubMed